Actorise 40 Injection (Darbepoetin Alfa)

Medicine overview

Actorise 40 Injection contains darbepoetin alfa, a medicine used to treat anemia associated with chronic kidney disease. It belongs to a group of medicines called erythropoiesis-stimulating agents (ESAs), which encourage the body to produce red blood cells.
People with chronic kidney disease may develop anemia because their kidneys produce insufficient erythropoietin, a hormone needed for red blood cell production. Actorise helps replace this biological activity and may reduce the need for blood transfusions.
The medicine comes in a prefilled syringe containing 40 mcg of darbepoetin alfa. Treatment requires medical supervision and regular blood monitoring.

What it is used for

Actorise 40 Injection is indicated for treating anemia caused by chronic kidney disease. It may be prescribed for patients receiving dialysis and those who have not started dialysis.
The treatment stimulates red blood cell production and helps reduce the need for blood transfusions.
Darbepoetin alfa is also used for certain cases of chemotherapy-associated anemia. However, this additional indication has not been independently confirmed for the exact Actorise 40 product. Its verified product-specific indication is anemia associated with chronic kidney disease.
The medicine is not intended to provide immediate correction of severe anemia.

How it works

Healthy kidneys produce erythropoietin, a hormone that signals the bone marrow to manufacture red blood cells. Chronic kidney disease can reduce the production of this hormone, contributing to anemia.
Actorise contains darbepoetin alfa, a laboratory-produced protein designed to act like natural erythropoietin.
It attaches to erythropoietin receptors in the bone marrow and stimulates the development of red blood cells.
As red blood cell production increases, hemoglobin levels may gradually improve. Hemoglobin is the protein responsible for carrying oxygen throughout the body.
Treatment aims to reduce the need for blood transfusions while avoiding excessive increases in hemoglobin.

How it is taken

Actorise 40 Injection must be administered according to the prescribing doctor's instructions.
It is administered beneath the skin (subcutaneous injection) or directly into a vein (intravenous injection), depending on the prescribed treatment.
The doctor determines the appropriate dose and administration frequency based on the patient's condition, body weight, hemoglobin measurements and response to treatment.
Important administration instructions include:

Administration should be performed by a healthcare professional or by a patient or caregiver who has received appropriate training.

Check the medicine before administration. Do not use the solution if it contains visible particles or appears discolored.

Do not shake the prefilled syringe.

Do not mix the medicine with other injectable medicines unless compatibility has been established.

Use the prefilled syringe only once.

Dispose of used needles and syringes in an appropriate sharps container.

Attend scheduled blood tests and medical appointments.

If an injection is missed, contact the prescribing healthcare professional for instructions. Do not administer an additional injection to compensate for a missed dose.

Important warnings

Uncontrolled high blood pressure: Darbepoetin alfa must not be used in patients with uncontrolled hypertension. Blood pressure should be adequately controlled before treatment and monitored regularly.
Cardiovascular complications: Erythropoiesis-stimulating agents can increase the risk of serious cardiovascular complications, including heart attack, stroke, blood clots and death. Higher hemoglobin targets can increase these risks.
Blood clot formation: Patients may develop deep vein thrombosis, pulmonary embolism or blood clots affecting dialysis vascular access. Sudden breathlessness, chest pain or swelling and pain in a limb require urgent medical assessment.
Cancer-related risks: Clinical studies involving erythropoiesis-stimulating agents have identified increased risks of tumor progression, recurrence or reduced survival in certain cancers. Patients with cancer require specialist assessment before receiving this class of medicine.
Pure red cell aplasia: Rarely, antibodies against erythropoietin may cause pure red cell aplasia, a condition in which the bone marrow stops producing sufficient red blood cells. An unexpected loss of treatment response requires medical investigation.
Seizures: Darbepoetin alfa may increase seizure risk, particularly in patients with chronic kidney disease. Patients with a history of seizures require appropriate monitoring.
Serious allergic reactions: Severe hypersensitivity reactions, including anaphylaxis, can occur. Facial swelling, breathing difficulties or a widespread allergic reaction require immediate medical attention.
Severe skin reactions: Serious skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported with darbepoetin alfa. Blistering, peeling skin or a severe rash requires urgent assessment.
Iron deficiency: Insufficient iron stores can reduce treatment response. Iron levels should be assessed before and during treatment, with supplementation when clinically indicated.
Patients should inform their healthcare professional about cardiovascular disease, previous stroke, blood clotting disorders, seizures and all medicines they are taking.

Side effects and monitoring

Common side effects
Depending on the underlying condition, darbepoetin alfa may cause:

Increased blood pressure.

Injection-site discomfort.

Peripheral edema, which causes swelling in the hands, feet or ankles.

Rash.

Shortness of breath.

Cough.

Serious or less common side effects
Important complications include:

Heart attack.

Stroke.

Deep vein thrombosis.

Pulmonary embolism.

Blood clots affecting dialysis vascular access.

Seizures.

Severe allergic reactions.

Serious skin reactions.

Pure red cell aplasia.

When medical attention is needed
Seek immediate medical attention for chest pain, sudden breathing difficulties, symptoms of stroke, seizures, facial swelling or severe skin reactions.
Report persistent or worsening side effects to the prescribing healthcare professional.
Monitoring requirements
Regular monitoring is essential throughout treatment.
Healthcare professionals should monitor:

Hemoglobin levels and treatment response.

Blood pressure.

Iron stores, including ferritin and transferrin saturation.

Unexpected reductions in hemoglobin.

Signs of cardiovascular or thromboembolic complications.

Hemoglobin measurements help clinicians assess treatment response and reduce the risk of excessive red blood cell production.

Pregnancy

There are insufficient human pregnancy data to establish whether darbepoetin alfa increases the risk of birth defects or miscarriage.
Animal studies have identified certain reproductive and developmental effects.
Pregnant patients, or those planning pregnancy, should discuss treatment with their healthcare professional. The potential maternal benefits must be weighed against possible fetal risks.

Breastfeeding

It is unknown whether darbepoetin alfa passes into human breast milk or affects breastfed infants or milk production.
A healthcare professional should consider the mother's need for treatment, the benefits of breastfeeding and any potential risks to the infant.

Food and drink

Darbepoetin alfa is administered by injection, so its administration does not depend on meal timing.
Patients should continue following any dietary or fluid restrictions recommended for their underlying medical condition.
Adequate iron availability is important for red blood cell production. A healthcare professional may recommend iron supplementation if testing identifies insufficient iron stores.

Storage

Store Actorise 40 Injection in a refrigerator at 2°C–8°C.
Do not freeze.
Protect the medicine from light and avoid shaking the prefilled syringe.
Keep the medicine out of children's reach.
Follow the product's supplied storage instructions and obtain professional advice if its storage conditions have been compromised.